Review Article
Trifarotene: A Novel Therapeutic Option for Acne
Table 1
Important clinical trials of trifarotene
| Drug(s) | Location(s) | Indication | Phase | Identifier | Sponsor | Status |
| Trifarotene cream vs vehicle cream | France, Germany, Spain | Lamellar ichthyosis | II | NCT03738800; EudraCT 2018-003272-12; 18-ICH-001 | Mayne Pharma International Ltd. | Ongoing | Trifarotene cream | USA | Early cutaneous T-cell lymphoma | I | NCT01804335; 2012–0710; NCI-2014-01377 | MD Anderson Centre; Galderma R&D | Completed | Trifarotene cream vs vehicle cream and tazarotene | USA | Acne vulgaris | II | NCT01616654; RD.06. SPR18223 | Galderma R&D | Completed | Trifarotene cream | USA | Acne vulgaris | III | NCT03915860; RD.06. SPR.118295 | Galderma R&D | Ongoing | Trifarotene cream | Multinational | Acne vulgaris | III | NCT02189629; EudraCT 2014-001755-23 | Galderma R&D | Completed | Trifarotene cream vs vehicle cream | Multinational | Acne vulgaris | III | PERFECT 2; NCT02556788; EudraCT 2016-002540- 13 | Galderma R&D | Completed | Trifarotene cream vs vehicle cream | Multinational | Acne vulgaris | III | PERFECT 1; NCT025566369; EudraCT 2016-002860- 15 | Galderma Research and Development (R&D) | Completed |
|
|